On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis.
about
Influence of aggregation and route of injection on the biodistribution of mouse serum albuminOccurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort AnalysisOxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.Immunogenicity to biologics: mechanisms, prediction and reduction.Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS.A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.Challenges and approaches for the development of safer immunomodulatory biologics.Liquid formulations for long-term storage of monoclonal IgGs.Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS.Novel chemical degradation pathways of proteins mediated by tryptophan oxidation: tryptophan side chain fragmentation.Aggregation, immune complexes and immunogenicity.Liquid formulations for stabilizing IgMs during physical stress and long-term storage.A Review on Recent Advances in Stabilizing Peptides/Proteins upon Fabrication in Hydrogels from Biodegradable Polymers.Flow microscopy imaging is sensitive to characteristics of subvisible particles in peginesatide formulations associated with severe adverse reactions.Disulfide-bridging PEGylation during refolding for the more efficient production of modified proteins.Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
P2860
Q28538961-726B96A2-AFC1-4580-97F1-F8ABBC383AE8Q28553133-901DA682-9A12-4AC4-9B44-45EE3006AD3EQ30402355-853E6302-37C5-4E55-931E-83098B229B60Q34296526-81489F6E-6E5B-4655-A40C-70D110A9FD67Q36001691-6D9651A9-5D71-43CC-8BBF-F9888DFE2791Q36979271-0196871D-A3C3-46E4-A4A8-6FF49CB25E51Q38048706-57590618-B2C8-4869-A851-234D5E7ABAD7Q38075798-0240384E-F552-4073-8B34-F1F7A1957AB6Q38093772-2EA4CC14-82AF-42C5-9E95-370CE988549CQ38318567-29A88B01-29F2-4DE5-82B5-969E9AFC9F83Q38798188-9081920E-20B3-4069-9708-3DEC72791164Q38982627-593FD5DF-A08B-4CA3-B3F9-B4303EC68273Q39109386-05187A0E-37F4-4385-B812-E1A48B283ED4Q43024178-A65FB708-3E55-4398-9DA1-FE825DF58D06Q44480024-E0C6D9DC-6785-4371-8CA0-345629A39460Q49965730-9235C85B-B5B5-4254-8944-FC09FF476EEDQ50153560-5E8C1739-B123-4C23-B593-E8A1B0F129B7Q50850473-415F99C1-6F07-4F14-9A89-EFBE96695802Q54311380-2BAFD542-D5E8-4F1B-9D01-207943BE8302Q54939538-425BDADC-671B-469B-9259-940E22439715
P2860
On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
On the role of aggregates in t ...... ients with multiple sclerosis.
@ast
On the role of aggregates in t ...... ients with multiple sclerosis.
@en
type
label
On the role of aggregates in t ...... ients with multiple sclerosis.
@ast
On the role of aggregates in t ...... ients with multiple sclerosis.
@en
prefLabel
On the role of aggregates in t ...... ients with multiple sclerosis.
@ast
On the role of aggregates in t ...... ients with multiple sclerosis.
@en
P2093
P356
P1476
On the role of aggregates in t ...... ients with multiple sclerosis.
@en
P2093
Huub Schellekens
Miranda M C van Beers
Wim Jiskoot
P304
P356
10.1089/JIR.2010.0086
P577
2010-10-01T00:00:00Z